Company news

Share this article:
CommonHealth Consumer Group (CCG) has announced the launch of EvoLogue, a full-service consumer agency that will provide insight-driven behavioral-marketing services to help improve the dialogue between consumers and healthcare professionals. The EvoLogue name "is a synthesis of the words 'evolving' and 'dialogue,'" said Meg Columbia-Walsh, managing partner and president of CCG, EvoLogue and eBusiness. "The name reflects our belief in the centrality of the healthcare professional-consumer dialogue to improving compliance, persistency and outcomes with both prescription and over-the-counter brands. And it conveys our commitment to providing superior strategic, multichannel communications, including advertising, CRM, interactive and proprietary behavioral-marketing services." The EvoLogue brand roster includes assignments from AstraZeneca, Pfizer, Merck, Johnson & Johnson, Novartis and Genentech. EvoLogue senior staff includes Shelagh Brooke, director of strategic planning; Mark Robinson, chief operating officer; Mark Kosak and Steve Pashkoff, co-chief creative officers; and Betsy Alvarez, director of business development.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.